CLOs on the Move

EYELA Tokyo Rikakikai Co

www.eyelausa.com

 
EYELA Tokyo Rikakikai Co is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Bio-Kinetic Clinical Applications

Bio-Kinetic Clinical Applications is a Springfield, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aeglea

With its acquisition of Spyre Therapeutics, Aeglea is shifting its disease focus to inflammatory bowel disease (IBD). Spyre combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for IBD.

Cullinan Oncology

Cullinan Oncology is focused on investing in and developing a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model. Sourced from the Cullinan dry lab as well as external collaborators, Cullinan`s assets are managed by a single, highly experienced team of oncology professionals and drug developers across a lean, capital efficient operating model.

AmnioLife

AmnioLife Corporation is a biotechnology company focused on the development and commercialization of a unique biologic suite of products designed to address unmet and underserved market needs with applications across multiple surgical specialties. We are committed to the development of novel biotechnology and regenerative therapeutics, primarily derived from placental origin. Currently we have filed a US provisional patent application on our core technology, ProLifixTM, an acellular collagen matrix. The Company has over 60 years of experience in biologics manufacturing and comercializaiton, and is led by Chris Broderick who recently launched a neurological tissue transplant technology and was responsible for over $10M in trending global sales.

Genentech

Genentech, Inc., is a biotechnology corporation which became a subsidiary of Roche in 2009.